An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

NCT03386838 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business objectives have changed.

Conditions

Head and Neck Cancer

Interventions

BIOLOGICAL: Nivolumab
DRUG: BMS-986205
BIOLOGICAL: Cetuximab
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Fluorouracil

Sponsor

Bristol-Myers Squibb